DK1558935T3 - Præparater med styret afgivelse - Google Patents

Præparater med styret afgivelse

Info

Publication number
DK1558935T3
DK1558935T3 DK03809236T DK03809236T DK1558935T3 DK 1558935 T3 DK1558935 T3 DK 1558935T3 DK 03809236 T DK03809236 T DK 03809236T DK 03809236 T DK03809236 T DK 03809236T DK 1558935 T3 DK1558935 T3 DK 1558935T3
Authority
DK
Denmark
Prior art keywords
matrix
release
agent
controlled release
release preparations
Prior art date
Application number
DK03809236T
Other languages
English (en)
Inventor
Vincent Lenaerts
Patricia Laure Ouadji-Njiki
Jonathan Bacon
Rachid Ouzerourou
Sonia Gervais
Miloud Rahmouni
Damon Smith
Original Assignee
Labopharm Inc
Labopharm Europe Ltd
Labopharm Barbados Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc, Labopharm Europe Ltd, Labopharm Barbados Ltd filed Critical Labopharm Inc
Application granted granted Critical
Publication of DK1558935T3 publication Critical patent/DK1558935T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03809236T 2002-10-25 2003-10-27 Præparater med styret afgivelse DK1558935T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28102602A 2002-10-25 2002-10-25
US50906202P 2002-10-25 2002-10-25
PCT/CA2003/001637 WO2004038428A2 (en) 2002-10-25 2003-10-27 Controlled-release compositions

Publications (1)

Publication Number Publication Date
DK1558935T3 true DK1558935T3 (da) 2008-11-17

Family

ID=34976756

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03809236T DK1558935T3 (da) 2002-10-25 2003-10-27 Præparater med styret afgivelse

Country Status (19)

Country Link
EP (1) EP1558935B1 (da)
JP (1) JP2006507276A (da)
KR (1) KR101120729B1 (da)
AT (1) ATE400819T1 (da)
AU (1) AU2003275854B9 (da)
BR (1) BR0315657A (da)
CA (1) CA2503361C (da)
DE (1) DE60322091D1 (da)
DK (1) DK1558935T3 (da)
EC (1) ECSP055748A (da)
ES (1) ES2310686T3 (da)
HK (1) HK1086475A1 (da)
MX (1) MXPA05004410A (da)
NO (1) NO20052515L (da)
NZ (1) NZ539869A (da)
PT (1) PT1558935E (da)
RU (1) RU2333745C2 (da)
SI (1) SI1558935T1 (da)
WO (1) WO2004038428A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
EP1917000A2 (en) 2005-07-07 2008-05-07 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
PL1931346T3 (pl) 2005-09-09 2013-01-31 Angelini Labopharm Llc Kompozycja trazodonu do podawania raz na dobę
CN100437113C (zh) * 2006-04-11 2008-11-26 汪运山 一种检测血液中非那西丁与醋氨酚浓度比值的试剂盒
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US20090169617A1 (en) * 2006-04-26 2009-07-02 Panagiotis Keramidas Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
CN100387988C (zh) * 2006-07-25 2008-05-14 山东省医药工业研究所 一种布洛伪麻那敏复方制剂的含量检测方法
WO2008095263A1 (en) 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
EP2203166B1 (en) 2007-10-16 2015-05-06 Paladin Labs Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
NZ589742A (en) 2008-05-27 2012-06-29 Univ Melbourne Methods of treating mammals with eustachian tube dysfunctions with betahistine
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
US20130039864A1 (en) * 2010-04-23 2013-02-14 Francois Ravenelle Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
RU2673818C2 (ru) 2012-11-30 2018-11-30 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN114177155B (zh) * 2020-09-08 2023-10-03 越洋医药开发(广州)有限公司 一种布洛芬控释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
AU8293498A (en) * 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
KR100507946B1 (ko) * 2001-01-31 2005-08-17 룀 게엠베하 운트 콤파니 카게 상이하게 피복된 펠렛 형태를 두 가지 이상 포함하는 다중 입상형 약제

Also Published As

Publication number Publication date
EP1558935B1 (en) 2008-07-09
RU2005115883A (ru) 2006-01-27
RU2333745C2 (ru) 2008-09-20
CA2503361C (en) 2012-02-28
KR20050088281A (ko) 2005-09-05
WO2004038428A2 (en) 2004-05-06
ATE400819T1 (de) 2008-07-15
AU2003275854B9 (en) 2009-08-27
ECSP055748A (es) 2005-08-11
AU2003275854A1 (en) 2004-05-13
AU2003275854B2 (en) 2008-09-11
CA2503361A1 (en) 2004-05-06
DE60322091D1 (de) 2008-08-21
HK1086475A1 (en) 2006-09-22
NO20052515D0 (no) 2005-05-25
KR101120729B1 (ko) 2012-04-23
SI1558935T1 (sl) 2008-12-31
NO20052515L (no) 2005-05-25
WO2004038428A3 (en) 2005-06-09
EP1558935A2 (en) 2005-08-03
ES2310686T3 (es) 2009-01-16
MXPA05004410A (es) 2005-11-23
JP2006507276A (ja) 2006-03-02
PT1558935E (pt) 2008-10-16
BR0315657A (pt) 2005-09-13
NZ539869A (en) 2007-09-28

Similar Documents

Publication Publication Date Title
NO20052515D0 (no) Frigjoringskontrollerte sammensetninger
ATE512659T1 (de) Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie
AR024492A1 (es) Formas de dosificacion farmaceutica para liberacion controlada que comprenden al menos un impulso ciclico
MX9707585A (es) Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
ME00482B (me) Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje
TWI235068B (en) Sustained-release pharmaceutical composition
DE69230475T2 (de) Verzögerte Freigabe Matrix für Arzneimittel
DE60132077D1 (de) Vitaminzusammenstellung mit verzögerter freigabe
TR200102880T2 (tr) Enjekte edilebilir naltrekson mikrokre bileçimleri ve bunlarìn eroin ve alkol tketiminin azaltìmì i‡in kullanìmì
JO2555B1 (en) Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent
BR0215262A (pt) Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
ATE431738T1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
DE60233760D1 (de) Netzwerkeinrichtungs-treiberarchitektur
DE69229881T2 (de) Tablette mit verzögerter freisetzung
AR020610A1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero
IE881195L (en) Ibuprofen sustained release matrix
ME00391B (me) Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
DE69925639D1 (de) Glicazidhaltige matrixtablette mit verzögerter wirkstoffverabreichung zur oralen anwendung
ATE306254T1 (de) Zubereitungen mit verbesserter kontrollierter freisetzung
ATE185266T1 (de) Schnell auflösende orale darreichungsform
EA200300110A1 (ru) Композиция элетриптана в виде частиц
MY142195A (en) Controlled-release compositions
UA86929C2 (ru) Композиция с контролируемым высвобождением
DE69627365D1 (de) Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten
BRPI0315657B8 (pt) formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição